- Article
- Source: Campus Sanofi
Dose Calculator for Fixed-Ratio Combination Pen Therapy
This calculator helps healthcare professionals determine the appropriate starting and titrated pen dose for a fixed-ratio combination of basal insulin and a GLP-1 receptor agonist. Because the pen delivers both components in a fixed ratio, correct dose selection is important to avoid under- or over-delivery of either component. The tool is intended to support, not replace, clinical judgment and the current prescribing information.
-copy.jpg/jcr:content/solipen%20banner%201920x565%20(1)%20copy.jpg)
“Approved by Egyptian Drug Authority: BF0065OA3974/052025. Invalidation date: 15/05/2026. Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg”
Approval Code: BF0065OA3974/052025 - Invalidation Date: 15/05/2026
Abbreviations:
OAD: Oral antidiabetic drug,FPG: Fasting plasma glucose
- Soliqua 100 units/ml + 50 micrograms/ml solution Summary of Product Characteristics. 8.8.224.
- Haluzík M, Cypryk K, Alvarez A, Lauand F, Corp Dit Genti V, Bakiner OS, Lim S. Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli- SWITCH study. Diabetes Obes Metab. 2025 May;27(5):2730-2739.
- Soliqua 100 units/ml + 33 micrograms/ml solution Summary of Product Characteristics. 8.8. 2024.
Because both drug components are delivered in a fixed ratio from a single pen, the maximum daily dose is capped to avoid exceeding the maximum recommended dose of either the insulin or the GLP-1 receptor agonist component. This means some patients who need higher basal insulin doses may not be suitable for this fixed-ratio formulation. Healthcare professionals should verify a patient's total daily dose needs fall within the pen's available range before prescribing.
The starting dose is generally based on the patient's current basal insulin dose, using a defined conversion approach to avoid an abrupt increase in total insulin exposure. A lower starting dose is often used when converting from higher insulin doses, given the added GLP-1 component. Healthcare professionals should follow the product-specific titration schedule and monitor fasting glucose closely after any dose change.
Titration is usually guided by fasting plasma glucose readings, with dose adjustments made at defined intervals until glycemic targets are reached, following the same general principle used for basal insulin titration. Patients should be counseled to report symptomatic hypoglycemia promptly, as this may require a downward dose adjustment. Regular follow-up during the titration phase helps optimize the dose more efficiently.
Confirm that you are a healthcare professional to continue reading.
Click login to continue